Detection of early biological and immunohistochemical markers for ductal carcinoma in situ and prediction of invasive breast cancer

2^nd World Congress on Breast Cancer

September 19-21, 2016 Phoenix, USA

Tanushri Mukherjee

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

Early diagnosis of breast cancer and effective treatment is the best modality. The breast ductal carcinoma in situ (DCIS) is an early, premalignant lesion in the evolution of invasive breast carcinoma. DCIS represents 20-45% of all new cases of mammographically detected breast cancer, and about 10% of all breast carcinomas. DCIS cases are identified as suspicious micro-calcifications through mammography but that often underestimates the pathologic extent of DCIS and the number of tumor foci. Early detection of DCIS is very important because it is a highly curable disease, with a 10-year cancer-specific survival rate of over 97%. Biomarkers which can be analyzed immunohistochemically in tissue blocks in a noninvasive and economic way. Early detection of DCIS with molecular markers allows early diagnosis and prevention of breast cancer. These markers are DEPDC1, NUSAP1, EXO1, RRM2, FOXM1, MUC1 and SPP1 which allow early detection of DCIS and invasive carcinomas especially in high risk cases with strong familial predisposition.